Gluais, Pascale, Jerôme Paysant, Cécile Badier-Commander, Tony Verbeuren, Paul M. Vanhoutte, and Michel Félétou. In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A 2 as endothelium-derived contracting factors. Am J Physiol Heart Circ Physiol 291: H2255-H2264, 2006. First published June 23, 2006 doi:10.1152/ajpheart.01115.2005.-In mature spontaneously hypertensive rats (SHR) and Wistar-Kyoto rats (WKY), acetylcholine and the calcium ionophore A-23187 release endotheliumderived contracting factors (EDCFs), cyclooxygenase derivatives that activate thromboxane-endoperoxide (TP) receptors on vascular smooth muscle. The EDCFs released by acetylcholine are most likely prostacyclin and prostaglandin (PG)H 2, whereas those released by A-23187 remain to be identified. Isometric tension and the release of PGs were measured in rings of isolated aortas of WKY and SHR. A-23187 evoked the endothelium-dependent release of prostacyclin, thromboxane A 2, PGF2␣, PGE2, and possibly PGH2 (PGI2 Ͼ Ͼ thromboxane A 2 ϭ PGF 2␣ ϭ PGE 2 ). In SHR aortas, the release of prostacyclin and thromboxane A 2 was significantly larger in response to A-23187 than to acetylcholine. In response to the calcium ionophore, the release of thromboxane A 2 was significantly larger in aortas of SHR than in those of WKY. In both strains of rat, the inhibition of cyclooxygenase-1 prevented the release of PGs and the occurrence of endothelium-dependent contractions. Dazoxiben, the thromboxane synthase inhibitor, abolished the A-23187-dependent production of thromboxane A 2 and inhibited by approximately one-half the endothelium-dependent contractions. U-51605, an inhibitor of PGI synthase, reduced the release of prostacyclin elicited by A-23187 but induced a parallel increase in the production of PGE 2 and PGF2␣, suggestive of a PGH 2 spillover, which was associated with the enhancement of the endothelium-dependent contractions. These results indicate that in the aorta of SHR and WKY, the endotheliumdependent contractions elicited by A-23187 involve the release of thromboxane A2 and prostacyclin with a most likely concomitant contribution of PGH2.
THE IMPAIRMENT of endothelium-dependent relaxations in the aorta of hypertensive rats (27, 47) was among the first examples of endothelial dysfunctions ever reported. Endothelial dysfunction is a generic term that encompasses many different disorders (11) . For instance, in the hypertensive salt-sensitive Dahl rat, the production of endothelial NO is reduced and the endothelin (ET) system is activated (8, 28) . In contrast, in the genetic model of spontaneously hypertensive rats (SHR), endothelial dysfunction is attributed to the release of an endothelium-derived contracting factor (EDCF) that counterbalances the effect of NO with no or only minor alteration in the production of the latter (29) . In response to acetylcholine, the endothelium-dependent contraction involves the production of reactive oxygen species, the activation of cyclooxygenase (COX)-1, the diffusion of EDCF, and the subsequent stimulation of thromboxane-endoperoxide (TP) receptors on vascular smooth muscle. Because inhibitors of thromboxane synthase do not affect or only poorly affect the endothelium-dependent contraction to acetylcholine, thromboxane A 2 is not the EDCF released by acetylcholine (14, 29) . As a matter of fact, in the aorta of SHR the EDCFs released by acetylcholine have been identified as prostaglandin (PG)H 2 and, paradoxically, prostacyclin (13, 14, 35) .
Interestingly, different forms of endothelial dysfunction are also observed in hypertensive patients. In patients with hypertension secondary to primary aldosteronism or to renovascular disease, who exhibit curtailed endothelium-dependent vasodilatations, the inhibition of COX does not improve the response to acetylcholine, suggesting that EDCF plays a minimal role in this endothelial dysfunction. In contrast, in essential hypertensive patients, indomethacin increases, and indeed almost normalizes, the vasodilator response to acetylcholine (45) . These findings demonstrate that in essential human hypertension vasoconstrictor products of COX are mainly responsible for the abnormal reaction to endothelium-dependent vasodilators.
Endothelium-dependent contractions are elicited not only by acetylcholine but also in response to other agonists that stimulate G protein-coupled receptors as well as to substances that increase endothelial intracellular Ca 2ϩ concentration in a receptor-independent manner (calcium ionophore, thapsigargin, cyclopiazonic acid). These responses are observed in rat arteries and in blood vessels from other species including the mouse and the human (34, 43, 45) . In the aorta of SHR, the characteristics of the endothelium-dependent contractions in response to the calcium ionophore A-23187 are similar to those elicited by acetylcholine. They also rely on the activation of endothelial COX and the stimulation of TP receptors (51) . However, despite these similarities, the EDCF(s) released by A-23187 may differ from those produced in response to acetylcholine. This would explain why the amplitude of the endotheliumdependent contractions elicited by A-23187 in arteries from rats and mice is consistently larger than that produced by acetylcholine (43, 51) .
The parallelism of the endothelial dysfunction as observed in SHR and in humans with essential hypertension is rather striking, and it warrants the conclusion that EDCFs must play a key role in the resulting endothelial dysfunction and that the nature of these contractile factors must be identified. Therefore, the purpose of the present study was to determine whether or not the endothelium-dependent contractions elicited by A-23187 in the aorta of the SHR can be explained, like those produced by acetylcholine, by the sole release of prostacyclin and PGH 2 .
MATERIALS AND METHODS
This study was performed in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals as well as with the guidelines established by the ethical committee of the Institut de Recherches Servier. The principal investigator of the present work has been granted a license from the French government to conduct animal research (License No. 03661 delivered by the Ministère de l'Agriculture et de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale).
Experiments were performed on thoracic aortas from 1-yr-old male SHR (400 g, n ϭ 108) and normotensive Wistar-Kyoto rats (WKY; 430 g, n ϭ 58; Charles River, l'Arbresle, France). The rats were anesthetized with pentobarbital sodium (50 mg/kg ip), and blood pressure was measured from the carotid artery (systolic blood pressure 188 Ϯ 5 and 108 Ϯ 4 mmHg in SHR and WKY, respectively; P Ͻ 0.05). The aorta was then dissected free, excised, and placed in cold modified Krebs-Ringer bicarbonate solution of the following composition (mM): 118 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2SO4, 25.0 NaHCO3, 0.026 edetate calcium disodium, and 11.1 glucose (control solution). In some aortas, the endothelium was removed from segments of various lengths by infusing a saponin solution (1 mg/ml for 20 s) that was subsequently flushed with control solution (10) . The aorta was then cut into rings (4 -5 mm in length). In some rings the isometric tension was recorded, whereas in others the release of prostanoids was studied.
Isometric tension recording. The rings were suspended in organ chambers (20 ml) that contained control solution (37°C) aerated with 95% O 2 and 5% CO2. They were connected to a force transducer to record isometric contraction. They were stretched progressively to reach the optimal point of their length-active tension relationship (ϳ2 g). Drug incubation time was at least 30 min for most of the experiments. Concentration-response curves were obtained in a cumulative manner. Each ring was exposed to only one set of cumulative concentrations of a given agonist. Contractile responses were expressed as a percentage of the reference contraction to KCl (60 mM), obtained in each ring at the beginning of the experiment (52) .
Release of PGs. These experiments were performed independently from the isometric tension experiments. To measure the release of prostanoids, rings were placed in thermostated minichambers containing 1 ml of control solution (37°C) aerated with 95% O 2 and 5% CO2. These aortic rings devoted to PG measurement were not subjected to passive tension. Although flow and dynamic changes such as acute stretch or pulsatile flow evoke the release of PGs (4, 5, 32) , in steady-state conditions and in the absence of flow the level of stretch or the level of transluminal pressure, per se, do not appear to affect PG release (4, 5, 7, 9) . The equilibration time was 1 h, during which the solution was changed every 15 min. The incubation period with drugs was 20 min, and agonists were applied for 10 min in presence of the drugs. Each ring was exposed once and to a single concentration of agonist. The aortic rings were then removed, and the minichambers were freeze clamped in liquid nitrogen and stored at Ϫ80°C for further analysis. The rings were placed in a dry hot box (60°C for 48 h), and the dry weight was measured (14) .
PGs were measured with the following enzyme immunoassay kits from Cayman Chemical (Ann Arbor, MI): 6-keto-PGF 1␣, thromboxane B2, PGE2, and PGF2␣. Undiluted 50-l samples were used, with the exception of the 6-keto-PGF1␣ measurement, which required a systematic 50ϫ dilution in control solution, and some samples that were subjected to a 2ϫ dilution for the assessment of PGE 2 and PGF 2␣. The various assays were performed as indicated by the manufacturer's procedure booklet.
Drugs. Acetylcholine hydrochloride, calcium ionophore A-23187, indomethacin, and N G -nitro-L-arginine were obtained from Sigma (La Verpillère, France). NS-398, SC-560, prostacyclin, PGH2, PGF2␣, PGE2, 9␣,11␣-azoprosta-5Z,13E-dien-1-oic acid (U-51605) and 9,11-dideoxy-9␣,11␣-methanoepoxy PGF2␣ (U-46619) were purchased from Cayman Chemical (Ann Arbor, MI). 3-[(6-amino-(4-chlorobenzensulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl]propionic acid (S-18886) and dazoxiben were synthesized at Institut de Recherches Servier (Suresnes, France). Drug concentrations are expressed as final molar concentrations in the bath solution.
Data analysis. Data are expressed as means Ϯ SE; n refers to the number of rats from which aortas were taken. Statistical analysis was performed by two-tailed Student's t-test for control and treatment comparisons and by one-way or two-way ANOVA for multiple comparisons followed by a Newman-Keuls or Bonferroni post hoc test, respectively, where appropriate. Differences were considered to be statistically significant when P was Ͻ0.05.
RESULTS

Endothelium-dependent and -independent contractions.
The calcium ionophore A-23187 (1 nM-1 M) produced a concentration-dependent and endothelium-dependent contraction in aortas of SHR. The concentration-response curve to A-23187 was significantly shifted to the left in the presence of N G -nitro-L-arginine (100 M). The TP receptor antagonist S-18886 (100 nM) abolished the endothelium-dependent contraction (Fig. 1) . In the presence of N G -nitro-L-arginine (100 M), the endothelium-dependent contractions in response to A-23187 were significantly larger in aortas of SHR than in those of WKY (Fig. 1) .
In the SHR, the maximal amplitude of the endotheliumdependent contractions produced by the calcium ionophore were significantly larger than those evoked by acetylcholine [maximal contraction in % of reference contraction to KCl: 46.7 Ϯ 2.7 (n ϭ 52) and 106.5 Ϯ 3.2 (n ϭ 40) for 10 M acetylcholine and 1 M A-23187, respectively; P Ͻ 0.05]. Furthermore, the contractions in response to A-23187 were sustained, whereas those observed in response to acetylcholine were transient (data not shown).
In SHR aortas with endothelium, the stable analog of thromboxane A 2 , U-46619, PGF 2␣ , PGE 2 , and the endoperoxide PGH 2 produced concentration-dependent contractions, whereas prostacyclin produced only a small increase in tone at the highest concentration tested (30 M). However, the presence of N G -nitro-L-arginine (100 M) or the denudation of the endothelium significantly and similarly shifted the concentration curves to the left in response to these various prostanoids. Under these conditions, the order of potency of the agonists was U-46619 Ͼ Ͼ PGF 2␣ ϭ PGH 2 Ͼ PGE 2 Ͼ PGI 2 . The prostanoid-induced contractions were virtually abolished by S-18886 (100 nM; Fig. 2) .
Release of PGs. In aortas of both SHR and WKY, A-23187 (1 M) evoked the release of 6-keto-PGF 1␣ (stable metabolite of prostacyclin), thromboxane B 2 (stable metabolite of thromboxane A 2 ), PGE 2 , and PGF 2␣ . In both strains, this release was endothelium dependent. The release of prostacyclin was 15-20 times larger than that of the other PGs. The release of thromboxane A 2 was significantly larger in preparations of SHR than in those of WKY (Fig. 3) .
The maximally effective concentration of A-23187 (1 M) evoked a significantly larger production and release of prostacyclin (ϳ1.5-fold increase) and, especially, thromboxane A 2 (6-fold increase) than the maximally effective concentration of acetylcholine (10 M). However, the production of PGE 2 and PGF 2␣ was similar in response to the two agents (Fig. 4) .
Cyclooxygenases. In both SHR and WKY aortas, the release of PGs (prostacyclin, thromboxane A 2 , PGE 2 , and PGF 2␣ ) induced by A-23187 (1 M) was not affected significantly by the presence of the preferential COX-2 inhibitor NS-398 (1 M). In contrast, the selective COX-1 inhibitor SC-560 (0.3 M) significantly inhibited the production of these various PGs, virtually abolishing that of prostacyclin and thromboxane A 2 (Fig. 5) .
In both WKY and SHR, the endothelium-dependent contractions induced by A-23187 were partially but significantly inhibited by NS-398 and prevented by the presence of SC-560. The combination of SC-560 plus NS-398 was not more effective than the presence of SC-560 alone. In contrast, the presence of NS-398, SC-560, or their combination did not significantly influence the contraction produced by U-46619 (Fig. 6) . The nonselective inhibitor of cyclooxygenase indomethacin (5 M) abolished both the endothelium-dependent contractions and the release of PGs (data not shown).
Thromboxane A 2 . In SHR aorta, the thromboxane synthase inhibitor dazoxiben (10 M) abolished the A-23187-dependent release of thromboxane A 2 (Fig. 7) , without affecting that of prostacyclin or PGE 2 (data not shown), and produced a partial but statistically significant inhibition of endothelium-dependent contractions. In the presence of dazoxiben, these contractions were no longer sustained but transient (Fig. 7) . Similar results were obtained in rings of WKY (data not shown).
Prostacyclin. The nonspecific prostacyclin synthase inhibitor U-51605 up to 1 M produced a concentration-dependent and partial but significant inhibition of A-23187-induced prostacyclin release without significantly affecting that of thromboxane A 2. In contrast, 0.5 and 1 M U-51605 produced a statistically significant increase in A-23187-induced PGE 2 and PGF 2␣ release (Fig. 8) . A-23187-induced endothelium-dependent contractions were significantly potentiated by 0.5 M U-51605 but were significantly inhibited by the compound at 1 M (Fig. 9) .
DISCUSSION
The present study demonstrates that in the SHR aorta endothelium-dependent contractions in response to the calcium ionophore A-23187, in contrast to those evoked by acetylcholine, involve the production and release of thromboxane A 2 .
The endothelium-dependent contractions elicited by A-23187 and acetylcholine share many similarities. Those evoked by A-23187 are abolished by S-18886, a selective TP receptor antagonist (36) , and SC-560, a potent and selective inhibitor of COX-1, but only partially inhibited by NS-398, a moderately selective inhibitor of COX-2 (21). The inhibitory effect of SC-560 is paralleled by a profound reduction of PG release. In contrast, the partial inhibition of the endotheliumdependent contractions by NS-398 is not associated with a significant decrease in PG production. Although NS-398 does not affect the responses to U-46619, indicating that this compound does not interact directly with TP receptors, a yetundetermined nonspecific effect of NS-398 may explain the partial inhibition of the endothelium-dependent contraction. Therefore, the endothelium-dependent contractions produced by A-23187, like those elicited by acetylcholine (29, 49, 50) , involve COX-1 activation and TP receptor stimulation.
However, the release of thromboxane A 2 is six times larger in response to A-23187 than in response to acetylcholine. This release is fully endothelium dependent and is abolished by the thromboxane synthase inhibitor dazoxiben (14) . The effect of dazoxiben appears specific, because the production of prostacyclin and PGE 2 is not affected. Acetylcholine-induced contractions are not affected by dazoxiben (3, 14, 22, 24, 29) , whereas those induced by A-23187 are reduced by half and over the whole concentration range of A-23187. These observations indicate that in the SHR aorta thromboxane A 2 is an EDCF released by A-23187. Although various PGs contract the smooth muscle cells by activating TP receptors, thromboxane A 2 is by far the most potent agonist (14) . The enhanced release of thromboxane A 2 in response to A-23187 certainly explains the larger amplitude and the difference in the kinetics (sustained vs. transient contractions) of the endothelium-dependent contractions produced by the calcium ionophore compared with those elicited by the muscarinic agonist. Indeed, in the presence of dazoxiben, the maximal amplitude and the transient nature of the time course of the contractions produced by the two mediators became similar.
The involvement of thromboxane A 2 has been previously reported in both SHR and WKY arteries, for instance, in the endothelium-dependent and -independent contractions in response to free radical generation (18) or in the endotheliumdependent component of the contractions evoked by ET-1 (41, 42) . The expression of TP receptors in vascular smooth muscle cells of the rat aorta is well documented (46), and hypertension does not appear to affect its expression (23) . However, in response to A-23187, the increased production of thromboxane A 2 , in the SHR aorta compared with that of WKY is sufficient to explain the enhanced EDCF-mediated responses in these hypertensive animals.
As dazoxiben abolished thromboxane A 2 synthesis but only produced a 50% inhibition of the endothelium-dependent contractions, another mediator(s) must be involved in the responses to A-23187. The endothelium-dependent contractions elicited by acetylcholine in the aorta of mature SHR and WKY most likely involve the release of prostacyclin (14) . This earlier conclusion was based on the following observations: 1) In isolated WKY and SHR aortic rings, prostacyclin is a contracting but not a relaxing factor. Indeed, prostacyclin is generally described as an endothelium-derived vasodilator, which, by stimulating its receptor [prostacyclin (IP) receptors] and activating adenylate cyclase, elevates intracellular cAMP concentration and produces relaxation of the vascular smooth muscle (48) . However, in WKY and SHR older than 30 wk, neither prostacyclin nor its stable analog iloprost produces a relaxation (14, 25, 35) . This is a phenotypic peculiarity of these two strains, because aortic rings from Fischer rats up to 23 mo of age relax in response to IP receptor agonists (35) . In both WKY and SHR, IP receptor gene expression decreases with age and, at any given age, is systematically less expressed in SHR than in WKY (33) . 2) Prostacyclin is a more potent contracting agent in SHR than in WKY. 3) Prostacyclin-and endothelium-dependent contractions both involve activation of TP receptors. 4) Prostacyclin is the most abundant PG released by acetylcholine and is of endothelial origin. 5) The time course of the release of prostacyclin is compatible with the time course of the observed endothelium-dependent contrac- tions. 6) The endothelium-dependent contractions and the release of prostacyclin are blocked by COX-1 inhibitors (14, 25, 29, 35, 45, 51, 53) . All the arguments developed above for a contribution of prostacyclin in acetylcholine-induced endothelium-dependent contractions also apply to A-23187. Because the calcium ionophore releases even more prostacyclin than acetylcholine does, it is legitimate to assume that prostacyclin contributes to the contraction produced by A-23187. In the rat aorta, prostacyclin is a weak agonist of the TP receptor and induces a contractile response, whereas its stable metabolite 6-keto-PGF 1␣ is virtually ineffective (14) . The rapid metabolism of prostacyclin may explain the transient nature of the endothelium-dependent contractions observed in response to either acetylcholine or A-23187 in presence of dazoxiben.
The involvement of prostacyclin in endothelium-dependent contractions to A-23187 is reinforced by the effects of the inhibitor of PGI 2 synthase U-51605. U-51605 is a stable analog of PGH 2 that inhibits both prostacyclin and thromboxane synthases, with a slight selectivity toward the former (14 -16).
It is also a partial agonist at TP receptors (14, 19, 30) . In the present study, U-51605 at a dose of 0.5 M produced a partial inhibition of prostacyclin release but did not affect that of thromboxane A 2 . However, at this concentration the compound already produces a substantial inhibition of TP receptors (14) . Paradoxically, the inhibition of the release of prostacyclin, one of the putative EDCFs, and the concomitant blockade of TP receptors were associated with the enhancement of the endothelium-dependent contractions to A-23187. This is only an apparent paradox, because the inhibition of prostacyclin release was compensated by a major increase in PGE 2 and PGF 2␣ production. PGH 2 is an unstable PG that undergoes spontaneous or enzymatic transformation toward PGF 2␣ and PGE 2 (2, 6, 14) . In endothelial cells, if the constitutive presence of the soluble PGE synthase associated with COX-1 is debatable, the parallel induction of the membrane-bound form of PGE-synthase with COX-2 is well documented (31, 37) . Because the induction of COX-2 has been suggested in the aorta of SHR and old WKY (1, 17) , the production of PGE 2 might be of enzymatic origin. However, it cannot be excluded, especially when PGI synthase is inhibited, that the rate of formation of PGH 2 exceeds its metabolism. Therefore, the production of PGE 2 and PGF 2␣ can partially represent spillover of PGH 2 . Functionally, in the rat aorta PGH 2 , PGE 2 , and PGF 2␣ all activate TP receptors and have similar potency and affinity (14) . A higher concentration of U-51605 (1 M) did not produce any further potentiation and even caused a small inhibition of the A-23187-induced endothelium-dependent contractions, most likely because of the overwhelming antagonistic properties of this compound toward TP receptors (14) . Tranylcypromine is often considered to be a nonspecific inhibitor of this enzyme (12) . However, under the present experimental conditions, the monoamine oxidase inhibitor did not affect the production of prostacyclin, therefore precluding its utilization (14) .
The amplitude of endothelium-dependent contraction in the SHR and WKY aorta is positively correlated with the level of arterial blood pressure (20) . However, chronic treatment with either a cyclooxygenase inhibitor or a TP receptor antagonist does not prevent the establishment of hypertension and does not decrease arterial blood pressure in SHR (26, 38, 54) but restores the endothelium-dependent relaxation in the aorta (44) . These results suggest that in SHR the production of EDCF is secondary to chronic hypertension and exacerbates the endothelial dysfunction. Similarly, in patients with essential hypertension, the endothelial dysfunction must precede the onset of high arterial blood pressure because in young genetically predisposed normotensive offspring of essential hypertensive patients the response to acetylcholine is already reduced (40) . Furthermore, antihypertensive agents do not have the same impact on endothelial function despite similar reduc- tion of arterial blood pressure (39) . Altogether the available data suggest that the endothelial dysfunction in SHR and in patients with essential hypertension is not directly related to blood pressure values and is probably genetically determined. The identification of the EDCFs released may help to design better treatments to restore proper endothelial function in hypertension.
In conclusion, the endothelium-dependent contractions elicited by A-23187 and acetylcholine in the aorta of SHR involve the release of different PGs: thromboxane A 2 , prostacyclin, and most likely PGH 2 for the former but only prostacyclin and PGH 2 for the latter.
